BioPartners Holdings AG: Clinical Phase III Trial Data Demonstrate Valtropin®'s Safety and Efficacy

Published: Aug 14, 2007

BAAR, Switzerland--(BUSINESS WIRE)--In a significant development for the emerging field of biosimilars, Biopartners’ recombinant human growth hormone (rhGH) - Valtropin® - has demonstrated equivalent safety and efficacy to its reference product. This welcomed communication follows some concerns raised by established biopharmaceutical companies about the safety of biosimilars.

Back to news